BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.21 USD
+0.50 (0.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $87.20 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 87.21 +0.50(0.58%)
Will BNTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
Other News for BNTX
WHO picks JN.1 variant for next set of COVID vaccines
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
What's Going On With Pfizer Stock On Thursday?
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents
Baron Focused Growth Fund Q1 2024 Shareholder Letter